Skip to main content

Table 5 Cytogenetic categories and response to therapy in the cohort of LEN patients

From: Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

A. All patient who received LEN for more than 3 months (N = 38)  
  Normal cytogenetic group Abnormal cytogenetic group p value
Categorized by MC only 64% 33% 0.07
Categorized by MC/FISH/SNP-A 64% 54% 0.4
B. Monotherapy (LEN only) patients (N = 27)   
  Normal cytogenetic group Abnormal cytogenetic group p value
Categorized by MC 60% 17% 0.08
only    
Categorized by MC/FISH/SNP-A 64% 44% 0.27
C. Patients with combination therapy of AZA + LEN (N = 11)  
  Normal cytogenetic group Abnormal cytogenetic group p value
Categorized by MC only 75% 67% 0.85
Categorized by MC/FISH/SNP-A 67% 75% 0.85
  1. LEN lenalidomide; MC metaphase cytogenetics; FISH fluorescence in situ hybridization; SNP-A single nucleotide polymorphism array karyotyping; AZA azacitidine.